Chroma Medicine

BOSTON, MA · Founded 2020 · CIK 0001967386 · Biotech · Acquired

Targeted in vivo genetic medicine delivery system for durable therapeutic effect

chromamedicine.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$135M
1 Form D · Mar 2023
43 months since last filing
Contracts
—
No federal contracts on record
Patents
40
0 granted · 40 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$135,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2800VYNE Therapeutics Inc.—$139M
2801Silverback Therapeutics—$139M
2802VANQUA BIO, INC.—$136M
2803Chroma Medicine—$135M
2804ANSA BIOTECHNOLOGIES, INC.—$123M
2805Frontier Medicines—$122M
2806Praxis Precision Medicine——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • KEVIN BITTERMANDirector
  • THOMAS CAHILLDirector
  • BIHUA CHENDirector
  • GEORGE GOLUMBESKIDirector
  • BRETT KAPLANExecutive Officer
  • MICHAEL KELLYDirector
  • JEFF MARRAZZODirector
  • VIC MYERExecutive Officer
  • PAOLA POZZIDirector
  • CATHERINE STEHMAN-BREENDirector · Executive Officer

Patents

USPTO · 0 granted of 40
  • Compositions And Methods For Epigenetic Regulation Of Gene Expressionapplication
  • Gene Silencingapplication
  • Compositions And Methods For Epigenetic Regulation Of Ciita Expressionapplication
  • Compositions And Methods For Epigenetic Regulation Of PCSK9 Expressionapplication
  • Gene Silencingapplication
  • Compositions And Methods For Epigenetic Regulation Of ZNF410 Expressionapplication
  • Compositions And Methods For Epigenetic Regulation Of Hbv Gene Expressionapplication
  • Compositions And Methods For Epigenetic Editingapplication
  • Compositions And Methods For Epigenetic Regulation Of Htt Expressionapplication
  • Compositions And Methods For Epigenetic Regulation Of ZNF410 Expressionapplication
  • Compositions And Methods For Epigenetic Editingapplication
  • Compositions And Methods For Epigenetic Regulation Of Transforming Growth Factor Beta Receptor 2 (TGFBR2) Expressionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.